The network analysis revealed that GEB may exert its therapeutic effects against CRC by modulating certain distinct targets, such as MAPK3, HSP90AA1, JUN, EGFR, CDK1, TNF CCND1, ESR1, PRKACA, and CCNA2. Here, MAPK3 is linked to colorectal carcinoma.